Company Announcements

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 7, 2024-- Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

To access the call, a live audio webcast will be available on the Investors section of the Company's website.

About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241007786927/en/

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Source: Revvity